Alogliptin benzoate; pioglitazone hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for alogliptin benzoate; pioglitazone hydrochloride and what is the scope of patent protection?
Alogliptin benzoate; pioglitazone hydrochloride
is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Alogliptin benzoate; pioglitazone hydrochloride has one hundred and one patent family members in forty-two countries.
Two suppliers are listed for this compound.
Summary for alogliptin benzoate; pioglitazone hydrochloride
| International Patents: | 101 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Clinical Trials: | 4 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for alogliptin benzoate; pioglitazone hydrochloride |
| DailyMed Link: | alogliptin benzoate; pioglitazone hydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for alogliptin benzoate; pioglitazone hydrochloride
Generic Entry Date for alogliptin benzoate; pioglitazone hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for alogliptin benzoate; pioglitazone hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Yonsei University | Phase 4 |
| Takeda | Phase 4 |
| Celltrion Pharm, Inc. | Phase 4 |
See all alogliptin benzoate; pioglitazone hydrochloride clinical trials
Pharmacology for alogliptin benzoate; pioglitazone hydrochloride
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Norway | 20064669 | ⤷ Try a Trial | |
| World Intellectual Property Organization (WIPO) | 2008093882 | ⤷ Try a Trial | |
| Hong Kong | 1138188 | SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE | ⤷ Try a Trial |
| Canada | 2677201 | PREPARATION SOLIDE COMPRENANT DE L'ALOGLIPTINE ET DE LA PIOGLITAZONE (SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE) | ⤷ Try a Trial |
| Japan | 5284968 | ⤷ Try a Trial | |
| Croatia | P20080509 | ⤷ Try a Trial | |
| European Patent Office | 2107905 | PRÉPARATION SOLIDE COMPRENANT DE L'ALOGLIPTINE ET DE LA PIOGLITAZONE (SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for alogliptin benzoate; pioglitazone hydrochloride
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1084705 | C01084705/05 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 62955 21.11.2013 |
| 1586571 | 16/2014 | Austria | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/13/844 (MITTEILUNG) 20130923 |
| 1586571 | 300640 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/844/001-007 20130923 |
| 1586571 | C 2014 011 | Romania | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN; NATIONAL AUTHORISATION NUMBER: EU/1/13/844/001 - EU/1/13/844/027; DATE OF NATIONAL AUTHORISATION: 20130919; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/844/001 - EU/1/13/844/027; DATE OF FIRST AUTHORISATION IN EEA: 20130919 |
| 1586571 | 132014902238640 | Italy | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN IN TUTTE LE FORME PROTETTE DAL BREVETTO DI BASE(VIPIDIA); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/13/844/001 A EU/1/13/844/027, 20130923 |
| 1586571 | 172 5006-2014 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: EU/1/13/844/001 - EU/1/13/844/027 20130919 |
| 1586571 | 92374 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE. FIRST REGISTRATION: 20130923 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
